The Medical Advisor

Key Points DMSO is a remarkably safe chemical that protects cells from otherwise fatal stressors (e.g., freezing, burning, shockwaves, ischemia) Since the heart, brain, and spinal cord are particularly vulnerable to injury, DMSO can produce miraculous results when those injuries happen Despite decades of research, many serious shortcomings exist with how we treat strokes (including brain bleeds), heart attacks, and spinal cord injuries As I will show here, had the FDA not sabotaged DMSO’s adoption, in addition to countless lives being saved, millions could have been protected from a lifetime of disability or paralysis Generated using DALL·E—OpenAI’s legacy image model Introduction If I were stranded on a desert island or knew the world was ending and I could only bring a few therapies with me, one of them, without a doubt, would be DMSO. This is because:  It effectively add...

Medically & Financially Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: September 2026 Quick Answer Merck & Co. remains the world's top cancer drug company by 2025 oncology revenue (~$35.4 billion, driven overwhelmingly by Keytruda) , followed by Roche (~$29–30 billion), AstraZeneca ($25.6 billion), Johnson & Johnson ($25.4 billion), and Bristol Myers Squibb (~$25.0 billion). Global oncology drug spending topped an estimated $291 billion in 2025 and is projected to reach roughly $467 billion by 2030 (IQVIA Institute), making cancer treatment the single largest therapeutic category in pharmaceuticals. The competitive picture keeps shifting: Merck's Keytruda faces a 2028 patent cliff, BMS's Revlimid has already lost roughly half its sales to generics, and a wave of Chinese-originated antibody-drug conjugates and PD-1×VEGF bispecifics is reshaping pipelines industry-wide. The oncology drug market looks nothing like it...